FDA Rejection & Stock Impact
Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage biotech focused on cortisol-modulating drugs. The company is reeling from an unexpected FDA decision at the end of 2025. On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve Corcept’s New Drug Application (NDA) for relacorilant (a cortisol modulator) as a treatment for patients with hypercortisolism (Cushing’s syndrome) (www.morningstar.com). The FDA concluded it could not find a favorable benefit-risk profile for relacorilant without additional evidence of efficacy (www.morningstar.com). Corcept’s management said it was “surprised and disappointed” by this outcome (www.morningstar.com). The news sent CORT’s stock plunging – shares fell about 50% in one day, dropping by $35.40 to close at $34.80 on Dec 31, 2025 (www.morningstar.com). This sharp decline has attracted a wave of shareholder class-action investigations alleging the company misled investors about relacorilant’s prospects. In late January 2026, the FDA publicly disclosed that it had repeatedly warned Corcept during pre-submission meetings about deficiencies in the relacorilant clinical program (the pivotal GRACE trial’s design) and told the company to expect significant review issues if it proceeded with the NDA (www.morningstar.com). The revelation that Corcept was cautioned in advance – yet had projected confidence – forms the crux of these class action concerns. Multiple law firms have since filed suits or solicited shareholders, claiming Corcept failed to disclose the FDA’s feedback and thus issued overly optimistic statements about its business and relacorilant’s approval probability (www.morningstar.com). The outcome of these legal actions remains to be seen, but they underscore serious questions about management’s transparency and judgment.
Dividend Policy & Shareholder Returns
Corcept Therapeutics does not pay any dividend and has never declared one. In fact, the company has stated it does not anticipate paying dividends in the foreseeable future, preferring to reinvest in growth (www.sec.gov). Accordingly, Corcept’s dividend yield is 0%, and traditional REIT metrics like FFO/AFFO are not applicable for this biotech. Instead of dividends, Corcept has opportunistically returned capital to shareholders via stock buybacks. The company repurchased a substantial amount of its own shares in recent years. Notably, in 2025 Corcept spent $245.9 million on share repurchases (net of option exercises), a dramatic increase from roughly $38 million repurchased in 2024 (www.biospace.com) (ir.corcept.com). These buybacks were funded out of operating cash flow and cash reserves, and took place as the stock rose into the $60–$70 range before the FDA setback. While buybacks can signal confidence, the timing now appears costly – much of 2025’s repurchase was done at prices well above the current ~$35 level, meaning the company expended cash on shares that subsequently lost half their value. Still, Corcept’s choice to eschew dividends is typical for a growth-focused pharma. Investors in CORT should base their return expectations on stock appreciation (and the company’s pipeline success) rather than income, as no dividend income is likely in the near term (www.sec.gov).
Balance Sheet & Leverage
Corcept entered 2026 with a strong balance sheet and minimal leverage. The company carries no significant debt on its books – it has no outstanding long-term loans or bonds – and thus faces no debt maturities that could pressure liquidity. In fact, interest expense was effectively zero in 2024–2025, reflecting the absence of borrowings (www.sec.gov) (www.sec.gov). Instead, Corcept finances its operations from internal cash flow and equity. As of year-end 2025, Corcept held $532.4 million in cash and investments (www.biospace.com). This sizable cash hoard (roughly 14–15% of the company’s recent market capitalization) provides a cushion for R&D spending and any contingencies. It’s worth noting that the cash balance did decline from $603 million a year prior, mainly due to the large share buybacks and ongoing R&D outlays (www.biospace.com). Even so, cash on hand still far exceeds total current liabilities. The working capital and liquidity position is robust, and Corcept has ample ability to fund operations and pipeline development without external debt. With no interest-bearing debt, coverage ratios are a non-issue – in fact, Corcept earns interest income on its cash rather than paying interest expense. This conservative balance sheet gives Corcept financial flexibility as it navigates the relacorilant setback. The only long-term obligations on the balance sheet are modest lease liabilities and typical accrued expenses (ir.corcept.com). Management has indicated no immediate need to raise capital; the existing cash plus ongoing profits (Corcept remained profitable in 2025) should support its near-term trials and any response required by the FDA (www.biospace.com) (www.biospace.com). In short, leverage is essentially zero, and liquidity is strong – a key positive in an industry where many peers burn cash and rely on debt or dilution.
- Could blow past ChatGPT and trigger a 70X money surge
- Louie Navalier: $358M stake — live demo you can watch
- Three cornerstones to profit from the AI boom
Valuation & Outlook
After the recent sell-off, Corcept’s valuation has reset to more moderate levels, though it still prices in future growth. Prior to the FDA’s CRL announcement, CORT stock traded near all-time highs (~$70), reflecting high expectations for relacorilant’s approval and revenue ramp. At $70, the stock was valued at roughly 9–10× trailing sales and over 50× earnings (using 2025 estimates). The 50% share-price plunge to ~$35 has cut those multiples roughly in half. Corcept now trades around 4.7× 2025 sales (761 million in 2025 revenue (www.biospace.com)) and about 42× trailing earnings (2025 net income was $99.7M, or $0.82 per diluted share (www.biospace.com), which equates to a P/E in the low-40s at a $34–35 share price). On a forward-looking basis, the P/E should improve if earnings rebound. However, even a ~40× trailing P/E indicates the market is valuing Corcept more for its growth potential than its current earnings – not unusual for a biotech with a dominant niche product and pipeline.
Peer comparisons: Direct comps are limited, as few mid-cap biotechs have Corcept’s combination of an established profitable product and late-stage pipeline. Traditional valuation metrics like Price/FFO are not meaningful here (FFO/AFFO apply to REITs, not drug companies). A more relevant gauge is EV/Revenue: Corcept’s enterprise value (market cap ~$3.5–$4.0B minus net cash ~$0.53B) is about 3.9× 2025 revenues, which is in line with or slightly below other profitable orphan drug companies. For example, biotechnology firms with a single endocrinology product often trade at 4–6× sales if growth is expected, so CORT’s post-drop valuation is not obviously stretched. It’s also instructive to consider forward guidance: Despite the relacorilant delay, Corcept’s management reiterated optimism for growth. In February 2026, the company guided $900–$1,000 million in revenue for 2026 (www.biospace.com) – a bold 18%–31% jump from 2025’s actual sales. If Corcept can indeed approach $1 billion in sales by 2026, the current stock price would equal roughly 3.5× forward sales, and the P/E would compress (assuming margins hold). Achieving that growth likely hinges on no generic competition for Korlym and new revenue streams (discussed below). The market’s skepticism is evident in the stock’s depressed level – investors appear to be in “wait-and-see” mode regarding those assumptions.
Corcept’s stock performance over the past year reflects a wild ride: it outperformed for most of 2025 on strong Cushing’s drug sales and enthusiasm for relacorilant, then crashed on the FDA rejection. Even after halving, the stock still sits above where it traded a couple of years ago, thanks to substantial revenue growth since 2023. Analyst sentiment has likely tempered following the CRL; future valuation upside will depend on clearing key hurdles (resolving relacorilant’s issues or securing other approvals). In summary, CORT’s valuation has come down to more reasonable levels after the FDA setback – but it is not “cheap” in absolute terms, given looming risks. The stock still embeds expectations of continued growth and pipeline success. Investors should monitor how 2026 develops: if Corcept hits its revenue targets and salvages relacorilant (or wins approval for its cancer indication), the current multiple could prove justified. Conversely, any further hiccups (or an early Korlym generic entry) could pressure the valuation further.
Key Risks
Corcept faces several major risks that could impact its financial performance and stock trajectory:
– Regulatory/Pipeline Risk: The failure to obtain FDA approval for relacorilant in Cushing’s syndrome is a significant setback. To eventually secure approval, Corcept may need to conduct additional clinical trials or gather more evidence, incurring delay and cost (www.morningstar.com). There is no guarantee the FDA will approve relacorilant at all without substantially more data on efficacy. This uncertainty clouds the growth story, as relacorilant was expected to be the next growth driver. Further, regulatory trust is shaken – the FDA’s detailed CRL indicated the agency had warned about trial design deficiencies (www.morningstar.com), suggesting a risk that Corcept’s development approach was flawed. Upcoming pipeline candidates could face similar scrutiny.
– Generic Competition (Korlym): Corcept’s revenue is almost entirely from Korlym, its cortisol-blocking drug for Cushing’s. Korlym’s exclusivity is waning. In late 2023, Corcept lost a patent dispute to Teva regarding Korlym (apnews.com). This legal defeat opens the door for generic rivals to enter the market once remaining regulatory hurdles clear. The timing of generics is uncertain (Corcept may appeal or have other patents), but the risk is imminent. A generic mifepristone (Korlym) launch could erode Corcept’s sales sharply, given Korlym’s >$750M annual revenue. Corcept might be forced to cut price or lose market share quickly if a cheaper generic alternative becomes available. Since Korlym represents the vast majority of current revenue (nearly 100% in 2025), this is an existential threat to Corcept’s cash flows if it materializes.
– Concentration & Competition in Cushing’s: Even aside from generics, Corcept’s reliance on one niche market (Cushing’s syndrome) is a vulnerability. Korlym faces competition from other Cushing’s treatments: for example, Recorlev (levoketoconazole, approved 2021) and Isturisa (osilodrostat, approved 2020) are newer drugs targeting endogenous Cushing’s syndrome. These alternatives, marketed by Xeris and Recordati respectively, could capture patients, especially if Korlym’s advantages diminish or if payers seek options. While Corcept’s 2024 revenue growth (40% YoY) suggested strong demand for Korlym (ir.corcept.com), increased uptake of competing medications or pricing pressure could slow future growth (ir.corcept.com). The small patient population means competitors are fighting over the same pie. If Korlym’s share even modestly declines due to competition or side-effect profiles, Corcept’s growth could stall.
– Litigation and Reputation Risk: The mounting shareholder lawsuits pose legal and financial risk. While such securities class actions often get settled by insurance, they can still divert management attention and potentially lead to financial penalties or stricter oversight. More concerning is the underlying allegation – that management withheld material FDA feedback. If evidence in the case reveals deeper governance issues or intentional misrepresentation, it could damage Corcept’s credibility with investors and regulators. In a worse scenario, regulatory bodies like the SEC could investigate. Even if the lawsuits are settled, Corcept may incur legal costs and must grapple with a trust deficit among shareholders.
– Execution Risk & Cost Inflation: Corcept’s ambitious growth plan entails heavy R&D and commercialization spending. The company significantly ramped its SG&A expenses in 2025 (selling/general expenses jumped ~60% in 2025 YoY, likely to support pipeline and pre-launch activities), which cut into earnings (www.biospace.com) (www.biospace.com). There is a risk that expenses continue rising (for example, if a new Phase 3 trial for relacorilant is required, or if a new salesforce is built for an oncology launch) without a commensurate increase in revenue. This could squeeze margins and turn Corcept’s current profits into losses. Management’s track record on forecasting is also in question – they projected $900+M revenue for 2025 but delivered $761M (www.biospace.com), missing initial guidance by a wide margin. Some of that miss was due to factors like a pharmacy distribution hiccup in early 2025 (ir.corcept.com) and perhaps conservatism post-patent loss, but it underscores forecast uncertainty. If future guidance proves optimistic, investors risk overpaying for unattained growth.
– Market Risk & Volatility: Like many biotech stocks, CORT is subject to high volatility around news flow. Future FDA decisions (such as the upcoming ovarian cancer indication discussed below), clinical trial readouts, or patent appeal outcomes could all swing the stock dramatically. Broader market conditions (e.g. biotech sector sentiment, interest rates affecting growth stock valuations) also pose risk. An investment in Corcept entails riding through potentially sharp swings, as evidenced by the recent 50% single-day drop. This volatility can be exacerbated by the relatively narrow shareholder base and modest trading volume for a mid-cap stock.
In summary, Corcept’s key risks center on its dependence on one product amid looming generic and competitive challenges, and the uncertainties in its pipeline/regulatory path forward. These factors, combined with the fallout from perceived management missteps, create a complex risk profile that investors must weigh against the company’s past profitability and future potential.
Red Flags and Concerns
Beyond the fundamental risks above, several red flags have emerged in Corcept’s recent narrative, raising questions about management’s credibility and corporate governance:
– Overconfidence vs. FDA Warnings: Perhaps the most glaring issue is the disconnect between Corcept’s public optimism and the FDA’s private caution. Throughout 2024 and 2025, Corcept’s executives touted relacorilant’s prospects, repeatedly stating that the NDA review was “progressing towards approval by the end of [2025]” (ir.corcept.com) and that relacorilant could become the “new standard of care” for hypercortisolism (ir.corcept.com). As late as Q1 2025, CEO Dr. Joseph Belanoff expressed unwavering confidence in relacorilant’s efficacy and safety profile, conveying optimism to investors and even reiterating a lofty revenue guidance for 2025 (ir.corcept.com) (ir.corcept.com). However, we now know the FDA had serious concerns about the pivotal trial design and had warned Corcept “on several occasions” about potential inadequacies (www.morningstar.com). Management did not disclose these concerns publicly. The fact that Corcept was “surprised” by the CRL, despite advance signals from regulators, suggests either willful ignorance or poor communication internally. This raises a red flag: investors are left wondering if management was overly optimistic to the point of being misleading (as the lawsuits allege) or if they genuinely misjudged the situation. Neither explanation inspires confidence. The episode casts doubt on the reliability of management’s commentary on pipeline programs going forward.
– Aggressive Growth Claims: In mid-2025, Corcept’s leadership made an eye-opening long-term projection – stating they were “more confident than ever” that the company could grow its hypercortisolism franchise from $3 billion to $5 billion in annual revenue within 3–5 years (www.globenewswire.com). Considering 2024 revenue was $675M, this implied an almost unprecedented 5× to 7× increase in a relatively short period. Such a claim is a red flag for potentially unrealistic expectations. It’s unclear what combination of new approvals, market expansion, or pricing was assumed. Now, with relacorilant delayed and generic competition nearing, that $3–5B revenue target appears extremely far-fetched. This situation suggests a pattern of over-promising. If management was willing to put out such an aggressive goal, investors should scrutinize other forward-looking statements carefully. The disparity between rosy projections and subsequent reality (a halved stock price and lower 2025 earnings) is stark.
– Insider Knowledge & Stock Transactions: The class action filings imply that Corcept’s insiders knew more about relacorilant’s risks than they let on (www.morningstar.com). While there have not been specific accusations of illicit insider trading, it’s notable that Corcept executed large share repurchases in 2025 at high prices, essentially using shareholder cash to buy stock while potential storm clouds (FDA pushback) were on the horizon. One might question if the board attempted to buoy the stock or signal confidence via buybacks despite brewing issues. No direct evidence of wrongdoing is public, but the optics are sensitive – it’s a governance red flag if management persisted with buybacks or bullish forecasts knowing that FDA feedback was negative. This will be an area to watch if any insider emails or testimony emerge in the lawsuit discovery process.
– Handling of Patent Litigation: Corcept’s approach to the Korlym patent litigation also raises some concern. The company lost its case against Teva in late 2023 (apnews.com), yet in guidance and commentary around that time, management did not significantly adjust 2025 expectations. The 2025 revenue guidance of $900–$950M was reiterated in Q1 2025 (ir.corcept.com), despite the patent loss that theoretically could allow a generic entry earlier than planned. It’s possible management assumed an appeal or settlement would avert a 2025 generic launch (indeed no generic launched that year), but the lack of transparent discussion about how the patent loss might impact future sales is notable. Investors would have benefited from more clarity on this issue. The silence or minimal disclosure on the patent risk, coupled with the optimistic guidance, can be viewed as a red flag regarding how forthcoming management is about threats to the core business.
– Surge in SG&A and Opacity of Expenses: As mentioned, Corcept’s selling, general & admin costs ballooned in 2025 (up ~60% to $449M (www.biospace.com)). While some increase is expected to support growth initiatives, the scale of this jump is unusual. The company hasn’t fully broken down what drove this – whether it’s commercial team expansion, higher legal fees (possibly patent and lawsuit-related), or one-time events. The lack of detailed explanation might concern investors about expense control and whether some of these costs will recur. If significant dollars were spent preparing for relacorilant’s launch (marketing, medical education, etc.), those funds may have been wasted given the CRL. This can be seen as a red flag in capital allocation: management bet big on a timely approval that did not occur. Going forward, shareholders will expect more prudent spending or at least better justification for expense lines.
Overall, the red flags center on management credibility and transparency. Corcept’s leadership painted a very bullish picture that did not align with reality. Trust, once dented, can suppress a stock’s valuation until management proves itself again. Investors will be watching forthcoming earnings calls and presentations for more measured, candid communication. It will be important for Corcept to reset expectations and rebuild confidence by under-promising and over-delivering, rather than the opposite.
Open Questions
In the wake of recent events, several open questions remain that will determine Corcept’s trajectory from here:
– What is the path forward for relacorilant in Cushing’s? Corcept insists it is working with the FDA “to determine the best path forward” for the relacorilant NDA in hypercortisolism (www.biospace.com) and remains confident that ultimately the drug will be approved. The critical questions are what additional evidence will the FDA require and how long might approval be delayed. Will Corcept need to run another full Phase 3 trial (which could take years), or can it gather supplemental data (e.g. re-analyzing existing trials or using real-world evidence)? The timeline here is pivotal – a quick resolution could revive relacorilant’s prospects, whereas a multi-year delay would reduce its commercial window (given approaching generics and other competitors). Investors will be looking for updates on FDA meetings or new trial plans in 2026. Until clarity emerges, relacorilant’s future (and the significant investment in it) remains uncertain.
– Can relacorilant succeed in other indications (e.g. oncology)? Corcept isn’t giving up on relacorilant – notably, it also has an application pending in oncology. The company completed the Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, and the data were promising enough to file an NDA in that setting. The FDA has accepted that NDA with a target decision date of July 11, 2026 (www.biospace.com). This presents an alternate avenue for relacorilant to reach the market (for a different use) even as the Cushing’s indication is on hold. Open questions: Will the oncology NDA face similar scrutiny or is the data more clear-cut? How large is the addressable market (platinum-resistant ovarian cancer is an area of high unmet need, but typically a smaller opportunity than Cushing’s due to shorter treatment duration)? If approved in ovarian cancer, can relacorilant be a meaningful revenue stream on its own? Investors will watch for the outcome of the FDA’s review mid-2026. A win there could partially offset the Cushing’s delay and validate Corcept’s drug in a new domain.
– What is the resolution and impact of Korlym’s patent/generic situation? After losing the patent case to Teva (apnews.com), it’s unclear whether Corcept has appealed the decision or is seeking a settlement to delay generic entry. The timeline for a generic Korlym launch is an open question with huge implications. If Teva (or another generic firm) launches mifepristone for Cushing’s in 2026, Corcept’s Korlym sales could erode rapidly. Does Corcept have any remaining patent or market exclusivity defenses? Will it attempt to switch patients to relacorilant (if that were approved as a replacement) to protect market share? Or could Corcept negotiate some royalty deal with generic challengers to retain a portion of sales? Each scenario leads to different financial outcomes. Investors are essentially in suspense on whether Korlym’s ~$750M/year monopoly is safe for another few years or on the brink of ending. Clarity on this may not come until either an appellate court ruling or an announcement by Corcept/Teva. Until then, modeling Corcept’s future cash flows remains difficult – this binary event could make a difference of hundreds of millions in revenue.
– How will the shareholder class actions play out? While such lawsuits are commonplace after big stock drops, the specificity of the allegations (that Corcept knew of FDA issues and failed to warn investors) means the case’s discovery phase could be telling. Open questions include: Might Corcept reach an early settlement, and if so, will insurance fully cover it or will it hit earnings/cash? Will any internal documents or emails emerge that paint management’s actions in a bad light (potentially prompting management changes or governance reforms)? It’s also worth asking if any SEC inquiry might follow – the Hagens Berman firm has even solicited whistleblowers (www.globenewswire.com), suggesting they suspect possible malfeasance. A formal SEC investigation has not been announced, but if it were, that would elevate this issue beyond a civil matter. In any case, the lawsuit could drag on for a year or more. Investors will want to see how Corcept responds – with defensive denial, quiet settlement, or tangible steps to improve disclosure practices. The outcome could influence the company’s reputation and how stringently it communicates going forward.
– Will Corcept diversify its portfolio? The recent turmoil underscores the danger of being a one-product company. An open question is whether Corcept will take strategic actions to diversify. It does have other compounds in development (e.g. dazucorilant for ALS, miricorilant for NASH/MASH, and additional oncology trials) (www.businesswire.com) (ir.corcept.com), but all are early-stage or unproven. Will Corcept accelerate any of these programs or seek partnerships to bring in new opportunities? Alternatively, with its strong cash position, could Corcept consider acquisitions or in-licensing to broaden its pipeline? So far, management has focused on its internal pipeline. But the question remains if the company can evolve from a single-product reliance to a more diversified rare-disease player. Any moves in this direction (or lack thereof) will be closely watched. A failure to diversify means Corcept’s fortunes remain tied to one theme (cortisol modulation), which could be risky if scientific or competitive winds shift.
– Can management restore credibility? Finally, a more qualitative but crucial question: how will Corcept’s leadership regain the market’s trust after this episode? Will there be management changes or board refreshment to satisfy investors that lessons have been learned? The CEO and team must now navigate the company through damage control with regulators and investors alike. Their communications in the next few quarters – regarding relacorilant updates, guidance realism, and risk disclosure – will be scrutinized. If they adopt a more transparent stance (for example, openly discussing FDA feedback or contingency plans), it could help rebuild confidence. Conversely, any hint of sugar-coating or denying problems could further alienate stakeholders. This is an open question whose answer will unfold in how management behaves and delivers on promises in 2026. The stakes are high: Corcept is fundamentally a solid business (profitable, with a clear niche), but it is at a crossroads where execution and honesty are paramount.
In conclusion, Corcept Therapeutics finds itself in a moment of challenge and change. The FDA’s rejection of relacorilant has not only cut the company’s market value in half, but also spotlighted issues in how the company managed expectations. The stock’s future will hinge on addressing these open questions. If Corcept can resolve the relacorilant impasse, fend off generic competition, and perhaps diversify its revenue base, it could emerge stronger in the long run. However, if the risks materialize negatively – prolonged approval delays, a Korlym generic launch, or further credibility hits – CORT could struggle to regain its former valuations. Investors should stay alert to upcoming milestones (FDA meetings, legal updates, and quarterly results) as they assess whether this “FDA rejection alert” is a temporary setback or a sign of deeper issues. For now, caution is warranted until more information is available and the company proves it can get back on track in both execution and transparency. (www.morningstar.com) (apnews.com)
For informational purposes only; not investment advice.